Recruiting studies: Refractory Microsatellite Stable Colorectal Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Combination Immunotherapy for the Treatment of Chemotherapy-refractory Metastatic MSS CRC
Phase 1/Phase 2 · 1 location(s) · Dan Feng · NCT07281716 Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cem
Phase 1/Phase 2 · 6 location(s) · National Cancer Institute (NCI) · NCT07147231 Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tip
Phase 2 · 2 location(s) · Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRS · NCT06522919 Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metas
Phase 1 · 8 location(s) · National Cancer Institute (NCI) · NCT06654037 Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Micros
Phase 2 · 6 location(s) · Stingray Therapeutics · NCT06589440

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.